A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).

被引：0
|
作者：
Govindan, Ramaswamy
Awad, Mark M.
Gadgeel, Shirish M.
Pachter, Jonathan A.
Patrick, Gloria
Denis, Louis J.
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Henry Ford Canc Inst, Detroit, MI USA
[4] Verastem Inc, Needham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9148
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [22] 31507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
    Gadgeel, Shirish M.
    Miao, Jieling
    Riess, Jonathan W.
    Mack, Philip C.
    Gerstner, Gregory James
    Burns, Timothy F.
    Taj, Asma
    Akerley, Wallace L.
    Dragnev, Konstantin H.
    Moon, James
    Gandara, David R.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [24] A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)
    Camidge, D. Ross
    Pachter, Jonathan
    Koustenis, Andrew
    Patrick, Gloria
    Spigel, David R.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [25] Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Mori, Shunta
    Liu, Jie
    Yamauchi, Toyohiro
    Sakae, Yuta
    Ohashi, Akihiro
    Kobayashi, Susumu S.
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
    Pinto, L. Masfarre
    Parreira, A. S. D. F. M.
    Unanua, N. Castro
    Rocha, P.
    Ruiz, I. Morilla
    Sanchez, L. Teijeira
    Clave, S.
    Gorro, N. Navarro
    Mora, R. Bach
    Sanchez, I.
    Campos, M. A. Galindo
    Garcia, A. Taus
    Martinez, A. Azkarate
    Fabregat, R. Marse
    Paricio, B. Bellosillo
    Arasanz, H.
    Aguillo, M. Martinez
    Arriola, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
    Pellini, B.
    Ganesan, V.
    Wan, F.
    Sankararaman, S.
    Manyanont, S.
    Akhave, N.
    Baggstrom, M.
    Ward, J.
    Waqar, S.
    Morgensztern, D.
    Govindan, R.
    Devarakonda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210
  • [28] Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
    Wu, Markus Y.
    Zhang, Eric W.
    Strickland, Matthew R.
    Mendoza, Dexter P.
    Lipkin, Lev
    Lennerz, Jochen K.
    Gainor, Justin F.
    Heist, Rebecca S.
    Digumarthy, Subba R.
    CANCERS, 2021, 13 (14)
  • [29] Real World Efficacy and Safety of Sotorasib in US Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
    Zhou, K. I.
    Lin, C.
    Tseng, C. -L.
    Ramnath, N.
    Dowell, J. E.
    Kelley, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S337 - S338
  • [30] A Phase 1B Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations
    Alexander, M.
    Tirunagaru, V. G.
    Doebele, R. C.
    Wrangle, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S361 - S361
12345